Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL28087875 | 1.00 | AKR1B1 (0.35) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| Phosphoric Acid SCHEMBL27686073 | 1.00 | AKR1B1 (0.35) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| Phosphoramidic Acid SCHEMBL27743483 | 0.93 | AKR1B1 (0.33) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL13062482 | 0.90 | — | — | |
| SCHEMBL37362 | 0.90 | — | — | |
| SCHEMBL574324 | 0.90 | — | — | |
| SCHEMBL477499 | 0.90 | — | — | |
| SCHEMBL22720619 | 0.90 | AKR1B1 (0.41) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL22720618 | 0.90 | AKR1B1 (0.41) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL6272445 | 0.90 | AKR1B1 (0.41) | AKR1B1LMNAL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024105673-A1 | COMPOSITIONS AND METHODS FOR TREATING RETINAL DISEASES | SKIP THERAPEUTICS LTD. (IL) | 2024-05-23 | — | — | WO | claimed |
| WO-2024009306-A1 | COMPOSITIONS AND METHODS FOR TREATING PRIMARY CILIARY DYSKINESIA | SKIP THERAPEUTICS LTD. (IL) | 2024-01-11 | — | — | WO | claimed |
| EP-3591052-B1 | RESTORATION OF THE CFTR FUNCTION BY SPLICING MODULATION | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2023-08-30 | — | — | EP | claimed |
| WO-2023105527-A1 | MUC5-TARGETED ANTISENSE OLIGONUCLEOTIDES AND RELATED METHODS FOR MODULATING EXPRESSION OF MUC5AC AND MUC5B | SPLISENSE LTD. (IL) | 2023-06-15 | — | — | WO | claimed |
| US-20230142669-A1 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | SPLISENSE LTD. (IL) | 2023-05-11 | — | — | US | claimed |
| WO-2023017512-A1 | ANTISENSE OLIGONUCLEOTIDES FOR MODULATING EXON SKIPPING IN CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) | SPLISENSE LTD. (IL) | 2023-02-16 | — | — | WO | claimed |
| EP-4125933-A1 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | Splisense Ltd. (IL) | 2023-02-08 | — | — | EP | claimed |
| WO-2023281514-A1 | NUCLEIC ACID MOLECULE AND ITS USE | RNA MORPH LTD (IL) | 2023-01-12 | — | — | WO | claimed |
| EP-4028503-A1 | SYSTEMS AND METHODS FOR IN-VITRO MODELING OF NEURODEGENERATIVE DISEASES | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2022-07-20 | — | — | EP | claimed |
| US-20220220486-A1 | COMBINATION TREATMENTS FOR CYSTIC FIBROSIS CHARACTERIZED BY A 3849 + 10KB C-TO-T CFTR MUTATION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2022-07-14 | — | — | US | claimed |
| WO-2020194321-A1 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | SPLISENSE LTD. (IL) | 2020-10-01 | — | — | WO | claimed |
| EP-3510148-A1 | HIV CLINICAL PLAN | Excision Biotherapeutics, Inc. (US) | 2019-07-17 | — | — | EP | claimed |
| EP-3465213-A1 | METABALOMICS AND VIRAL DIAGNOSTICS SUITE | Excision Biotherapeutics, Inc. (US) | 2019-04-10 | — | — | EP | claimed |
| US-20180155723-A1 | RESTORATION OF THE CFTR FUNCTION BY SPLICING MODULATION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2018-06-07 | — | — | US | claimed |
| WO-2018049372-A1 | HIV CLINICAL PLAN | EXCISION BIOTHERAPEUTICS INC (US) | 2018-03-15 | — | — | WO | claimed |
| WO-2017205460-A1 | METABALOMICS AND VIRAL DIAGNOSTICS SUITE | EXCISION BIOTHERAPEUTICS, INC. (US) | 2017-11-30 | — | — | WO | claimed |
| WO-2016112350-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING LYSOSOMAL STORAGE DISORDERS | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2016-07-14 | — | — | WO | claimed |
| US-20150211010-A1 | Restoration Of The CFTR Function By Splicing Modulation | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2015-07-30 | — | — | US | claimed |
| EP-2898072-A1 | RESTORATION OF THE CFTR FUNCTION BY SPLICING MODULATION | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2015-07-29 | — | — | EP | claimed |
| WO-2014045283-A1 | RESTORATION OF THE CFTR FUNCTION BY SPLICING MODULATION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-03-27 | — | — | WO | claimed |